268 related articles for article (PubMed ID: 34212895)
1. Chemopreventive Effect of Statin on Hepatocellular Carcinoma in Patients With Nonalcoholic Steatohepatitis Cirrhosis.
Pinyopornpanish K; Al-Yaman W; Butler RS; Carey W; McCullough A; Romero-Marrero C
Am J Gastroenterol; 2021 Nov; 116(11):2258-2269. PubMed ID: 34212895
[TBL] [Abstract][Full Text] [Related]
2. Statin Use and Reduced Hepatocellular Carcinoma Risk in Patients With Nonalcoholic Fatty Liver Disease.
Zou B; Odden MC; Nguyen MH
Clin Gastroenterol Hepatol; 2023 Feb; 21(2):435-444.e6. PubMed ID: 35158055
[TBL] [Abstract][Full Text] [Related]
3. Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease.
Yang JD; Ahmed F; Mara KC; Addissie BD; Allen AM; Gores GJ; Roberts LR
Hepatology; 2020 Mar; 71(3):907-916. PubMed ID: 31309602
[TBL] [Abstract][Full Text] [Related]
4. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
[TBL] [Abstract][Full Text] [Related]
5. Statin Use and the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.
Goh MJ; Sinn DH; Kim S; Woo SY; Cho H; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Hepatology; 2020 Jun; 71(6):2023-2032. PubMed ID: 31556128
[TBL] [Abstract][Full Text] [Related]
6. The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease.
Lee TY; Wu JC; Yu SH; Lin JT; Wu MS; Wu CY
Int J Cancer; 2017 Oct; 141(7):1307-1314. PubMed ID: 28509327
[TBL] [Abstract][Full Text] [Related]
7. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES.
Simon TG; Bonilla H; Yan P; Chung RT; Butt AA
Hepatology; 2016 Jul; 64(1):47-57. PubMed ID: 26891205
[TBL] [Abstract][Full Text] [Related]
8. Incidence of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis or advanced liver fibrosis.
Behari J; Gougol A; Wang R; Luu HN; Paragomi P; Yu YC; Molinari M; Chopra K; Malik SM; Geller D; Yuan JM
Hepatol Commun; 2023 Jul; 7(7):. PubMed ID: 37395730
[TBL] [Abstract][Full Text] [Related]
9. Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis.
Hsiang JC; Wong GL; Tse YK; Wong VW; Yip TC; Chan HL
J Hepatol; 2015 Nov; 63(5):1190-7. PubMed ID: 26208777
[TBL] [Abstract][Full Text] [Related]
10. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.
Ascha MS; Hanouneh IA; Lopez R; Tamimi TA; Feldstein AF; Zein NN
Hepatology; 2010 Jun; 51(6):1972-8. PubMed ID: 20209604
[TBL] [Abstract][Full Text] [Related]
11. Statin Use is Protective Against Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Case-control Study.
German MN; Lutz MK; Pickhardt PJ; Bruce RJ; Said A
J Clin Gastroenterol; 2020 Sep; 54(8):733-740. PubMed ID: 31567625
[TBL] [Abstract][Full Text] [Related]
12. Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma.
Kawamura Y; Arase Y; Ikeda K; Seko Y; Imai N; Hosaka T; Kobayashi M; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Ohmoto Y; Amakawa K; Tsuji H; Kumada H
Am J Gastroenterol; 2012 Feb; 107(2):253-61. PubMed ID: 22008893
[TBL] [Abstract][Full Text] [Related]
13. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
Massoud O; Charlton M
Clin Liver Dis; 2018 Feb; 22(1):201-211. PubMed ID: 29128057
[TBL] [Abstract][Full Text] [Related]
14. Combined Use of Aspirin and Statin is Associated With a Decreased Incidence of Hepatocellular Carcinoma.
Singh J; Wozniak A; Cotler SJ; Dhanarajan A; Aldrich D; Park D; Kasia C; Schmidt B; Scaglione S
J Clin Gastroenterol; 2022 Apr; 56(4):369-373. PubMed ID: 33883511
[TBL] [Abstract][Full Text] [Related]
15. Statins Are Associated With a Decreased Risk of Severe Liver Disease in Individuals With Noncirrhotic Chronic Liver Disease.
Sharma R; Simon TG; Hagström H; Lochhead P; Roelstraete B; Söderling J; Verna EC; Emond J; Ludvigsson JF
Clin Gastroenterol Hepatol; 2024 Apr; 22(4):749-759.e19. PubMed ID: 37121528
[TBL] [Abstract][Full Text] [Related]
16. Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study.
Kim G; Jang SY; Han E; Lee YH; Park SY; Nam CM; Kang ES
Int J Cancer; 2017 Feb; 140(4):798-806. PubMed ID: 27861855
[TBL] [Abstract][Full Text] [Related]
17. Incidence and predictors of hepatocellular carcinoma in NAFLD without diagnosed cirrhosis: a nationwide real-world U.S. study.
Huang DQ; Tran S; Barnett S; Zou B; Yeo YH; Cheung R; Nguyen MH
Hepatol Int; 2024 Apr; 18(2):540-549. PubMed ID: 38079023
[TBL] [Abstract][Full Text] [Related]
18. Should Patients With NAFLD/NASH Be Surveyed for HCC?
Reig M; Gambato M; Man NK; Roberts JP; Victor D; Orci LA; Toso C
Transplantation; 2019 Jan; 103(1):39-44. PubMed ID: 30080818
[TBL] [Abstract][Full Text] [Related]
19. Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis.
Aminian A; Al-Kurd A; Wilson R; Bena J; Fayazzadeh H; Singh T; Albaugh VL; Shariff FU; Rodriguez NA; Jin J; Brethauer SA; Dasarathy S; Alkhouri N; Schauer PR; McCullough AJ; Nissen SE
JAMA; 2021 Nov; 326(20):2031-2042. PubMed ID: 34762106
[TBL] [Abstract][Full Text] [Related]
20. Association of statin treatment with hepatocellular carcinoma risk in end-stage kidney disease patients with chronic viral hepatitis.
Kim HW; Joo YS; Kang SC; Koh HB; Han SH; Yoo TH; Kang SW; Park JT
Sci Rep; 2022 Jun; 12(1):10807. PubMed ID: 35752695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
